Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
Sponsor: Hospices Civils de Lyon
Summary
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab. The aim of the study is to characterize the immune cells modulations under anti-PD-1 +/- anti-CTLA4 and identify the differences between responder and non-responder patients.
Official title: Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2019-10-10
Completion Date
2021-06-15
Last Updated
2026-07-20
Healthy Volunteers
No
Conditions
Interventions
Blood and biopsy sampling
Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression. Skin biopsies will be taken at week 1, week 7, week 53 or at the progression.
Locations (1)
Service de Dermatologie, Centre Hospitalier Lyon Sud (HCL)
Pierre-Bénite, France